Smartlab Europe

Thermo Fisher Scientific Collaborates to Introduce Fully Automated Cell Line Automation Platform

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Clinical Trial Patient Recruitment and Site Selection

Maximizing the speed and quality of drug development requires a data-driven approach to patient enrollment and site identification, where precision analytics meet operational excellence in the 2026 clinical landscape.

Global Clinical Trials with Local Expertise in 2026

Navigating the complexities of multi-region clinical research requires a balance of global oversight and deep local knowledge to ensure regulatory compliance and efficient patient recruitment across international sites.

Adaptive CRO Models in Clinical Development Strategy

Explore the evolution of flexible clinical research organization frameworks that use real-time data to adjust trial parameters, reduce uncertainty, and optimize outcomes for global biotech innovation in 2026.
- Advertisement -

Thermo Fisher Scientific, the world leader in serving science, and Celltrio, a leading manufacturer of robotics-based solutions for the life sciences industry, have announced their collaboration to bring a fully automated cell culture system to biotherapeutics customers.

The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the critical unmet market need for high-throughput automated cell line culturing and maintenance. Celltrio’s RoboCell systems distributed in Europe will now use Momentum software for work scheduling and data management. Thermo Fisher will also immediately take on exclusive responsibility for sales, installation, and support of the RoboCell system in Europe, with the possibility of extending into other geographies in the future.

“Cell line scale-up challenges have long stifled the full potential of biotherapy research. While researchers have been able to automate some aspects of cell line production, full automation has been well out of reach,” said Hansjoerg Haas, senior director and general manager, laboratory automation, Thermo Fisher Scientific. “By collaborating with Celltrio, we’re bringing together the capabilities that make fully automated cell line culturing a reality. With the ability to effectively scale processes, biotherapeutics customers can focus on getting their innovative therapies to patients, paving the way to a better, healthier world.”

Charlie Duncheon, CEO and co-founder, Celltrio, Inc. said, “The complementary expertise of Thermo Fisher and Celltrio offers a clear, powerful opportunity to help customers overcome a pressing roadblock. By offering Thermo Fisher’s intuitive Momentum workflow scheduling software with Celltrio’s end-to-end automation RoboCell platform, we can expand the RoboCell reach and amplify the impact of both solutions for biotherapeutics customers, benefitting the biopharma market and human health.”

With the Momentum workflow scheduling software, RoboCell users may define, execute, and monitor processes and workflows with an easy-to-use interface. The software’s intelligent data-driven decision-making capabilities and bi-directional communication also enable secure connectivity and traceability while ensuring laboratories boost their performance.

Latest stories

Related stories

Clinical Trial Patient Recruitment and Site Selection

Maximizing the speed and quality of drug development requires a data-driven approach to patient enrollment and site identification, where precision analytics meet operational excellence in the 2026 clinical landscape.

Global Clinical Trials with Local Expertise in 2026

Navigating the complexities of multi-region clinical research requires a balance of global oversight and deep local knowledge to ensure regulatory compliance and efficient patient recruitment across international sites.

Adaptive CRO Models in Clinical Development Strategy

Explore the evolution of flexible clinical research organization frameworks that use real-time data to adjust trial parameters, reduce uncertainty, and optimize outcomes for global biotech innovation in 2026.

Strategic CRO Partnerships in Modern Drug Development

Examining the shift from transactional outsourcing to collaborative alliances, where shared risk and integrated data drive clinical success in the 2026 pharmaceutical landscape.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »